As previously reported, Wedbush downgraded Werewolf Therapeutics (HOWL) to Neutral from Outperform with a price target of $1, down from $3. The firm notes the company reported updates from ongoing trials of WTX-124 and WTX-330. As a reminder, IL-2 INDUKINE WTX-124 is currently being investigated across solid tumors including melanoma, cSCC, GEJ, and in combination with pembrolizumab in melanoma, NSCLC, and RCC. While Wedbush notes early signs of efficacy among INDUKINE programs, it is moving to the sidelines due to cash constraints, as the company pursues strategic options to progress earlier stage INDUCER T cell engagers.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics downgraded to Neutral from Outperform at Wedbush
- Werewolf Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
- Clinical Momentum and Platform Validation Drive Undervalued Upside at Werewolf Therapeutics
- Werewolf Therapeutics Updates Pipeline and Outlines 2026 Priorities
- Werewolf Therapeutics provides pipeline update, review of INDUKINE data